|
KMID : 0191120130280010080
|
|
Journal of Korean Medical Science
2013 Volume.28 No. 1 p.80 ~ p.86
|
|
|
Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation
|
|
Lee Ho-Sup
Kim Yang-Soo
Kim Ki-Hyun
Kim Jin-Seok
Kim Hyo-Jung
Min Chang-Ki
Suh Cheol-Won
Eom Hyeon-Seok
Yoon Sung-Soo
Lee Jae-Hoon
Kim Min-Kyong
Kim Sung-Hyun
Bae Sung-Hwa
Mun Yeung-Chul
Jo Deog-Yeon
Chung Joo-Seop
|
|
|
Abstract
|
|
|
|
Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival. The purpose of our study was to show how of early response to bortezomib combined chemotherapy influences survival in patients with newly diagnosed MM who are ineligible for stem cell transplantation. We assessed patient responses to at least four cycles of bortezomib using the International Myeloma Working Group response criteria. The endpoints were comparisons of progression free survival (PFS) and overall survival (OS) between early good response group (A group) and poor response group (B group). We retrospectively analyzed data from 129 patients registered by the Korean Multiple Myeloma Working Party, a nationwide registration of MM patients. The 3 yr PFS for the A and B groups was 55.6% and 18.4%, respectively (P < 0.001). The 3 yr OS for the A and B groups was 65.3% and 52.9%, respectively (P = 0.078). The early response to at least four cycle of bortezomib before next chemotherapy may help predict PFS in patients with MM who are ineligible stem cell transplantation.
|
|
|
KEYWORD
|
|
|
Early Response, Multiple Myeloma, Bortezomib, Survival
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|